Evidence map›Paper›PMID 24462520›Full record

ArticleMolecular oncology2014

DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.

Tarek M A Abdel-Fatah, Roslin Russell, Devika Agarwal, Paul Moseley, Michael Ayotunde Abayomi, Christina Perry, Nada Albarakati, Graham Ball, Stephen Chan, Carlos Caldas and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. The Emerging Role of PRMT6 in Cancer.Frontiers in oncology · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.International journal of molecular sciences · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Tarek M A Abdel-FatahDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.
Roslin RussellDepartment of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK; Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Devika AgarwalSchool of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham NG11 8NS, UK.
Paul MoseleyDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.
Michael Ayotunde AbayomiDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.
Christina PerryDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.
Nada AlbarakatiDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.
Graham BallSchool of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham NG11 8NS, UK.
Stephen ChanDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.
Carlos CaldasDepartment of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK; Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Ian O EllisDivision of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham University Hospitals, Nottingham NG51PB, UK.
Srinivasan MadhusudanDepartment of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK; Division of Oncology, School of Medicine, University of Nottingham, Nottingham NG51PB, UK. Electronic address: srinivasan.madhusudan@nottingham.ac.uk.
Nottingham University Hospitals NHS Trust · GBNottingham Trent University · GBUniversity of Cambridge · GBUniversity of Nottingham · GB

Funding

Cancer Research UK 16942Medical Research Council MR/J008001/1
6 · The paper itself

Abstract

Short arm of chromosome 8 is a hot spot for chromosomal breaks, losses and amplifications in breast cancer. Although such genetic changes may have phenotypic consequences, the identity of candidate gene(s) remains to be clearly defined. Pol β gene is localized to chromosome 8p12-p11 and encodes a key DNA base excision repair protein. Pol β may be a tumour suppressor and involved in breast cancer pathogenesis. We conducted the first and the largest study to comprehensively evaluate pol β in breast cancer. We investigated pol β gene copy number changes in two cohorts (n = 128 &n = 1952), pol β mRNA expression in two cohorts (n = 249 &n = 1952) and pol β protein expression in two cohorts (n = 1406 &n = 252). Artificial neural network analysis for pol β interacting genes was performed in 249 tumours. For mechanistic insights, pol β gene copy number changes, mRNA and protein levels were investigated together in 128 tumours and validated in 1952 tumours. Low pol β mRNA expression as well as low pol β protein expression was associated high grade, lymph node positivity, pleomorphism, triple negative, basal-like phenotypes and poor survival (ps < 0.001). In oestrogen receptor (ER) positive sub-group that received tamoxifen, low pol β protein remains associated with aggressive phenotype and poor survival (ps < 0.001). Artificial neural network analysis revealed ER as a top pol β interacting gene. Mechanistically, there was strong positive correlation between pol β gene copy number changes and pol β mRNA expression (p < 0.0000001) and between pol β mRNA and pol β protein expression (p < 0.0000001). This is the first study to provide evidence that pol β deficiency is linked to aggressive breast cancer and may have prognostic and predictive significance in patients.

Indexed as

Gene DosageGene Expression Regulation, NeoplasticBreastBreast NeoplasmsCohort StudiesDNA Polymerase betaEstrogen Receptor alphaFemaleHumansPrognosisRNA, MessengerDNA Polymerase betaESR1 protein, humanEstrogen Receptor alphaRNA, MessengerBreast cancerPol βPredictive factorPrognostic factor

Identifiers

PMID24462520
PMCPMC5528629
OpenAlexW2134999555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.